Results 181 to 190 of about 344,100 (302)

Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients. [PDF]

Can J Infect Dis Med Microbiol
Bsat D, Safi D, Arabi M.
europepmc   +1 more source

Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. [PDF]

, 2020
Atrio, Jessica M, Coplon, Leah, Creinin, Mitchell D, Dean, Gillian, Gold, Marji, Grossman, Daniel, Mark, Alice, Perritt, Jamila, Raymond, Elizabeth G, Taylor, DeShawn, Upadhyay, Ushma D   +10 more
core   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Repurposing Drugs for the Treatment of COVID-19

Journal of Biotechnology and Bioindustry, 2021
openaire   +2 more sources

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019. [PDF]

Sci Rep
Jung DS, Cheon S, Kim CM, Seo JW, Sung SJ, Kim DY, Lee JH, Kim W, Kang J, Yun NR, Kim YR, Kim DM.   +11 more
europepmc   +1 more source

COVID-19 in Older Adults: Transfers Between Nursing Homes and Hospitals [PDF]

, 2020
Bonner, Alice, Levine, Stacie, Melady, Donald, Perry, Adam, Unroe, Kathleen T.   +4 more
core  

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

The Impact of COVID-19 on Obstructive Pulmonary Diseases: A Narrative Review of Long-Term Consequences and Vaccination Strategies. [PDF]

Health Sci Rep
Dalfardi B, Abtahi H, Edalatifard M, Mozaffari S, Rahimi B, Roostaei G, Khoshnam Rad N.   +6 more
europepmc   +1 more source

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Arthritis &Rheumatology, EarlyView.
Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim, Wendi Qian, Francis Dowling, Alan Salama, Rona M Smith   +4 more
wiley   +1 more source